Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

BioInvent International AB (BINV)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
38.000 -0.900    -2.31%
01/08 - Closed. Currency in SEK
Type:  Equity
Market:  Sweden
ISIN:  SE0015244520 
S/N:  65804362
  • Volume: 32,494
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 37.650 - 38.850
BioInvent International 38.000 -0.900 -2.31%

BioInvent International AB Company Profile

 
Get an in-depth profile of BioInvent International AB, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

118

Equity Type

ORD

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1 clinical trial for the treatment of solid tumors. It has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; collaboration and supply agreement with MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; and licensing agreement with CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Contact Information

Address The Gamma Building Ideongatan 1
Lund, 223 70
Sweden
Phone 46 4 62 86 85 50
Fax -

Top Executives

Name Age Since Title
Leonard Kruimer 63 2018 Independent Chairman of the Board
Kristoffer Bissessar 54 2020 Independent Director
Thomas O. Hecht 71 2020 Independent Director
Vincent Ossipow 56 2021 Independent Director
Rienk Offringa - 2017 Member of Scientific Advisory Board
Falk Nimmerjahn - 2017 Member of Scientific Advisory Board
Bernd Robert Seizinger 68 2018 Independent Director
Alexander Maximiliaan Marie Eggermont - 2021 Member of Scientific Advisory Board
Mark Cragg - - Member of Scientific Advisory Board
Alexander Rudensky - 2017 Member of Scientific Advisory Board
Stephen Beers - - Member of Scientific Advisory Board
Natalie Brittenham Berner 35 2022 Independent Director
Elin Birgersson 40 2024 Employee Representative Director
Laura Lassouw-Polman 46 2024 Independent Director
Nanna Luneborg 50 2022 Independent Director
Tomas Wall 44 2025 Employee Representative Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BINV Comments

Write your thoughts about BioInvent International AB
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email